Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Seizert Capital Partners LLC

Seizert Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% during the 3rd quarter, Holdings Channel reports. The firm owned 98,790 shares of the biopharmaceutical company’s stock after buying an additional 12,810 shares during the period. Regeneron Pharmaceuticals comprises approximately 2.4% of Seizert Capital Partners LLC’s investment portfolio, making the stock its 15th biggest holding. Seizert Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $55,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sage Mountain Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth $514,000. Jackson Thornton Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $519,000. QTR Family Wealth LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $227,000. Slow Capital Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.0% in the 3rd quarter. Slow Capital Inc. now owns 12,538 shares of the biopharmaceutical company’s stock valued at $7,050,000 after purchasing an additional 129 shares in the last quarter. Finally, Allstate Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $2,123,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,431 shares of company stock worth $5,733,521 in the last 90 days. 7.02% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on REGN shares. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Scotiabank lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. UBS Group lifted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $791.05.

Regeneron Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:REGN opened at $724.39 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a 50-day simple moving average of $750.43 and a 200-day simple moving average of $638.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The stock has a market capitalization of $76.13 billion, a P/E ratio of 17.43, a PEG ratio of 1.92 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.46 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.